Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.
about
Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding siteMoving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trialProfile of etravirine for the treatment of HIV infectionSimilar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysisAntiretroviral treatment 2010: progress and controversies.Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages.Authentic HIV-1 integrase inhibitors.Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials.The use of integrase inhibitors in treatment-experienced patients.Pharmacokinetic evaluation of etravirine.Inhibiting the HIV integration process: past, present, and the future.Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future.HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile.Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
P2860
Q27660224-68E94D36-A76F-44E3-BCEE-F0FF85ACBDEFQ28540037-1AC9B164-B355-4802-9254-C55C01EC0E93Q33635039-05885D7A-2AC1-4B2C-B5E0-A1AF5E123DB2Q33935930-81A3D57E-5196-4B02-8904-C6AD2C8ED61CQ34035275-0AA2B553-C7F4-41AB-A909-C9A763A75354Q34447780-048A5C9D-D21C-48DF-AB65-E0C5226402D7Q34518299-F81A3EF0-7C9B-4F72-B210-8E1088F7AB02Q34701261-BB1C24D8-D497-420D-A700-D1A2FBB73C12Q35119834-93CB0DA7-3731-4B15-B03E-F98D147644ACQ36145625-9BABA80D-A178-459B-BC33-36E49DC7D9E5Q37639881-47FB3AD6-D178-4F0F-AD3F-0406C7A474FFQ37644122-1F232C15-2C23-4F7C-90B8-BDB515DADF0FQ37809537-3F4A4AB6-CF40-4FD5-9FA3-F4F61812E392Q39352071-9E4F554C-B3E2-4933-80DF-C481E9A06A83Q39511996-3E3A94F9-389B-41DC-8806-448A62EFB529Q39548875-CDA40C5C-E93E-48E2-8A23-C31651436149Q39648233-00714BCA-4AC5-459F-802D-70272C7C5E85Q41875646-D73B86B8-A3A8-4871-A56C-FE4955999525Q43108044-85C774AB-CBEF-4532-8AFA-89B87AAB077AQ43760953-71D246B6-DBE5-400F-8F9B-8B2335C1B2BFQ54520623-C4850EBC-CA46-44FE-9C44-1839E89C478F
P2860
Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Raltegravir, etravirine, and r ...... rug-resistant HIV-1 infection.
@en
Raltegravir, etravirine, and r ...... rug-resistant HIV-1 infection.
@nl
type
label
Raltegravir, etravirine, and r ...... rug-resistant HIV-1 infection.
@en
Raltegravir, etravirine, and r ...... rug-resistant HIV-1 infection.
@nl
prefLabel
Raltegravir, etravirine, and r ...... rug-resistant HIV-1 infection.
@en
Raltegravir, etravirine, and r ...... rug-resistant HIV-1 infection.
@nl
P2093
P50
P1476
Raltegravir, etravirine, and r ...... drug-resistant HIV-1 infection
@en
P2093
Arkaitz Imaz
Enrique Ruiz de Gopegui
Estrella Caballero
M Angels Ribas
Manel Crespo
Marjorie Diaz
Melcior Riera
Sara Villar del Saz
P304
P356
10.1097/QAI.0B013E3181B17F53
P407
P577
2009-11-01T00:00:00Z